Education
About Us
Working with TipRanks
Follow Us
Chris Degnan Insider Profile
4 Followers
Chris Degnan, CFO at Verrica Pharmaceuticals, holds 2.28K shares in Urogen Pharma (Ticker: URGN), holds 10.00K shares in Galera Therapeutics (Ticker: GRTX), holds 3.00K shares in Verrica Pharmaceuticals (Ticker: VRCA).
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-67.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Chris Degnan holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Aug 15, 2018 - Aug 15, 2019
Return:-45.70%
The most profitable trade made by Chris Degnan
Chris Degnan's Trading History
Verrica Pharmaceuticals
Aug 15, 2018
CFO
Informative Buy
45.00K
$14.16K
Galera Therapeutics
Mar 14, 2023
CFO
Informative Buy
19.50K
$210.00
Urogen Pharma
Oct 09, 2025
CFO
Uninformative Buy
38.42K
$61.40K
List of latest transactions for each holding click on a transaction to see Chris Degnan's performance on stock
You May Also Like
Chris Degnan insider profile FAQ
What is the percentage of profitable transactions made by Chris Degnan?
The percentage of profitable transactions made by Chris Degnan is 0%.
What is the average return per transaction made by Chris Degnan?
The average return per transaction made by Chris Degnan is -67.80%.
What stocks does Chris Degnan hold?
Chris Degnan holds: VRCA, GRTX, URGN stocks.
What was Chris Degnan’s latest transaction?
Chris Degnan latest transaction was an Uninformative Buy of $38.42K.
What was Chris Degnan's most profitable transaction?
Chris Degnan’s most profitable transaction was an Informative Buy of VRCA stock on August 15, 2018. The return on the trade was -45.70%.
What is Chris Degnan's role in Verrica Pharmaceuticals?
Chris Degnan's role in Verrica Pharmaceuticals is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.